A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : PD-L1

Search Conditions:
Search Keyword : PD-L1
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: PD-L1
Appearance Frequency: 4082 time(s)
Long forms: 35

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
programmed death-ligand 1
(3731 times)
Neoplasms
(1662 times)
PD-1 (928 times)
NSCLC (579 times)
OS (417 times)
0 [Checkpoint Inhibitors in the Treatment of Upper Gastrointestinal Tract Tumors].
PD-1 ligand
(260 times)
Neoplasms
(99 times)
PD-1 (182 times)
CTLA-4 (30 times)
NSCLC (28 times)
2001 Laser capture microdissection-based expression profiling identifies PD1-ligand as a target of the nude locus gene product.
protein ligand 1
(42 times)
Neoplasms
(16 times)
NSCLC (11 times)
ICIs (7 times)
CTLA-4 (6 times)
2017 Near infrared photoimmunotherapy with avelumab, an anti-programmed death-ligand 1 (PD-L1) antibody.
PD-1 and its ligand
(8 times)
Neoplasms
(3 times)
PD-1 (2 times)
Abs (1 time)
EC (1 time)
2007 Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection.
anti-PD-ligand 1
(4 times)
Neoplasms
(2 times)
PD-1 (4 times)
CTLA-4 (2 times)
COP (1 time)
2017 Biomarkers to predict prognosis and response to checkpoint inhibitors.
programmed cell death 1
(3 times)
Molecular Biology
(1 time)
HNSCC (2 times)
CTLA-4 (1 time)
eTregs (1 time)
2018 Mouse-Derived Gastric Organoid and Immune Cell Co-culture for the Study of the Tumor Microenvironment.
programmed death receptor-1 and its ligand
(3 times)
Neoplasms
(1 time)
NSCLC (1 time)
OSA (1 time)
SLN (1 time)
2014 Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-line.
anti-PD-1 ligand
(2 times)
Hematology
(1 time)
PD-1 (2 times)
CLL (1 time)
DCs (1 time)
2020 Triggering interferon signaling in T cells with avadomide sensitizes CLL to anti-PD-L1/PD-1 immunotherapy.
programmed death protein-ligand 1
(2 times)
Neoplasms
(2 times)
PD-1 (1 time)
smRCC (1 time)
VEGFR2 (1 time)
2020 New emerging targets in cancer immunotherapy: the role of VISTA.
10  programmed death-ligand 1 receptor
(2 times)
Neoplasms
(2 times)
OS (2 times)
AR (1 time)
BMI (1 time)
2019 Prognostic markers in salivary gland cancer and their impact on survival.
11  1-PD-1-ligand
(1 time)
Biology
(1 time)
APCs (1 time)
CTLA-4 (1 time)
PD (1 time)
2003 T cell costimulatory pathways: blockade for autoimmunity.
12  demonstratedprogrammed death ligand-1
(1 time)
GI (1 time)
IHC (1 time)
NCCN (1 time)
2020 Gastric Cardia Adenocarcinoma with Metastasis to the Scalp: A Case Report.
13  PD-1 and its 2 B7 family ligands, B7-H1
(1 time)
Hematology
(1 time)
CTLs (1 time)
HA (1 time)
2007 Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.
14  PD-1 engagement to its ligand
(1 time)
Medicine
(1 time)
CMV (1 time)
PD-1 (1 time)
2006 Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction.
15  PD-1 ligand expression
(1 time)
Immunotherapy
(1 time)
CTLA-4 (1 time)
PD-1 (1 time)
SITC (1 time)
2016 Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation.
16  PD-1 ligand-positive T cells
(1 time)
Allergy and Immunology
(1 time)
IFN (1 time)
IL (1 time)
MTB (1 time)
2017 Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.
17  PD-1 on CD4+CD25+ Tregs, CD19+ cells and its ligand
(1 time)
Allergy and Immunology
(1 time)
BI (1 time)
2017 Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.
18  PD-1 on Tcells and its ligand
(1 time)
Biological Science Disciplines
(1 time)
APCs (1 time)
2018 Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells.
19  PD-1 on Tregs, B cell and its ligand
(1 time)
Allergy and Immunology
(1 time)
BI (1 time)
2017 Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients.
20  PD-1 receptor ligand
(1 time)
Immune System Diseases
(1 time)
PD-1 (1 time)
2014 Autoimmunity as a double agent in tumor killing and cancer promotion.
21  PD-1, namely, B7-H1
(1 time)
Allergy and Immunology
(1 time)
DCs (1 time)
PD-1 (1 time)
2002 Expression of programmed death 1 ligands by murine T cells and APC.
22  PD-1, the ligand of which
(1 time)
Antineoplastic Agents
(1 time)
PD-1 (1 time)
2019 Improved outcomes with pembrolizumab treatment in two cases of double cancer including non-small-cell lung cancer.
23  PD-1-PD-ligand 1
(1 time)
Allergy and Immunology
(1 time)
IFN (1 time)
IL (1 time)
MTB (1 time)
2017 Programmed death-1+ T cells inhibit effector T cells at the pathological site of miliary tuberculosis.
24  PD-L1 and TGF-beta than patients with advanced invasive thymic carcinoma
(1 time)
OS (1 time)
PFS (1 time)
TETs (1 time)
2018 Impact of PD-L1, transforming growth factor-beta expression and tumor-infiltrating CD8+ T cells on clinical outcome of patients with advanced thymic epithelial tumors.
25  PD-L1 and, more recently, chromosomal 9p24.1/CD274
(1 time)
Pathology
(1 time)
FISH (1 time)
IHC (1 time)
PD-L2 (1 time)
2018 Immune checkpoint blockade as a potential therapeutic strategy for undifferentiated malignancies.
26  PD-L1 IHC
(1 time)
Pathology
(1 time)
NSCLC (1 time)
2016 [Predictive PD-L1 immunohistochemistry for non-small cell lung cancer : Current state of the art and experiences of the first German harmonization study].
27  PD-L1 protein expression using two IHC assays, mRNA
(1 time)
Genetics, Medical
(1 time)
NSCLC (1 time)
2019 PD-L1 gene copy number and promoter polymorphisms regulate PD-L1 expression in tumor cells of non-small cell lung cancer patients.
28  PD-L1 TM
(1 time)
Neoplasms
(1 time)
OS (1 time)
PD-L1 ME (1 time)
PFS (1 time)
2020 Prognostic significance of EGFR, MUC1 and PD-L1 expressions in cases with triple negative breast cancer.
29  PD-L1High
(1 time)
Molecular Biology
(1 time)
ALDH (1 time)
PD-1 (1 time)
TNBCs (1 time)
2019 WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
30  plasma cells, are CD19-negative, and express B7-H1
(1 time)
Hematology
(1 time)
MM (1 time)
2010 A subpopulation of malignant CD34+CD138+B7-H1+ plasma cells is present in multiple myeloma patients.
31  production of T cells via interaction with its ligands, B7-H1
(1 time)
Allergy and Immunology
(1 time)
--- 2014 Negative role of inducible PD-1 on survival of activated dendritic cells.
32  programmed cell death ligand 1 antibody
(1 time)
Biomedical Engineering
(1 time)
Treg (1 time)
2019 Regulatory T Cells Tailored with pH-Responsive Liposomes Shape an Immuno-Antitumor Milieu against Tumors.
33  programmed cell death receptor-1
(1 time)
Allergy and Immunology
(1 time)
DCs (1 time)
LPS (1 time)
MSCs (1 time)
2017 Mesenchymal Stem Cells Upregulate the Expression of PD-L1 But Not VDR in Dendritic Cells.
34  Programmed Death Cell Ligand 1
(1 time)
Vascular Diseases
(1 time)
OS (1 time)
TIMs (1 time)
2017 Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
35  programmed death-1 molecule ligand 1
(1 time)
Allergy and Immunology
(1 time)
CVID (1 time)
HLA-DR (1 time)
Ig (1 time)
2012 Monocyte activation is a feature of common variable immunodeficiency irrespective of plasma lipopolysaccharide levels.